Table 1.
Patient demographics and clinical characteristics at regorafenib treatment initiation (pre- or post-inclusion of the ReDOS strategy in NCCN Guidelines)
| Characteristic | Study population (N = 703) |
|
|---|---|---|
| Pre-inclusion of ReDOS in NCCN Guidelines (n = 310) | Post-inclusion of ReDOS in NCCN Guidelines (n = 393) | |
| Age, years | ||
| Mean (SD) | 63.1 (12.3) | 65.2 (11.3) |
| Median (range) | 63 (34.0–89.0) | 67 (32.0–89.0) |
| Mean, n (%) | 175 (56.5) | 220 (56.0) |
| Race, n (%) | ||
| African American/Black | 39 (12.6) | 40 (10.2) |
| Asian | 14 (4.5) | 19 (4.8) |
| Hispanic | 39 (12.6) | 42 (10.7) |
| Unknown | 17 (5.5) | 70 (17.8) |
| White | 201 (64.8) | 222 (56.5) |
| US region, n (%) | ||
| Midwest | 88 (28.4) | 72 (18.3) |
| Northeast | 26 (8.4) | 36 (9.2) |
| South | 133 (42.9) | 207 (52.7) |
| West | 63 (20.3) | 78 (19.8) |
| Payer category, n (%)* | ||
| Commercial | 153 (49.4) | 150 (38.2) |
| Medicare Advantage | 157 (50.6) | 243 (61.8) |
| Charlson Comorbidity Index | ||
| Mean (SD) | 2.1 (2.2) | 2.4 (2.2) |
| Median (range) | 2.0 (0–13.0) | 2.0 (0–15.0) |
| Prior hospitalizations, n (%) | 100 (32.3) | 122 (31.0) |
| Mean number of visits (SD) | 1.5 (0.8) | 1.4 (0.8) |
|
Hand–foot skin reaction at baseline, n (%) |
55 (17.7) | 73 (18.6) |
| Hypertension at baseline, n (%) | 179 (57.7) | 249 (63.4) |
| Anti-EGFR treatment at baseline, n (%) | 82 (26.5) | 87 (22.1) |
| Anti-VEGF treatment at baseline, n (%) | 143 (46.1) | 181 (46.1) |
| Chemotherapy at baseline, n (%) | 252 (81.3) | 301 (76.6) |
| Trifluridine/tipiracil treatment at baseline, n (%) | 62 (20.0) | 74 (18.8) |
| Immunotherapy at baseline, n (%) | < 5 (–)† | 9 (2.3) |
| Follow-up time, months | ||
| Mean (SD) | 8.6 (9.0) | 6.9 (5.5) |
| Median (range) | 5.5 (0–47.7) | 5.5 (0–29.7) |
*The Clinformatics® database covers a proportion of the commercially insured and Medicare Advantage population in all 50 US states and Washington DC. Medicare is US medical insurance for eligible patients, including those aged ≥ 65 years or who have certain disabilities or conditions. Medicare beneficiaries may be covered under a traditional Medicare plan (government managed) or the Medicare Advantage plan (managed by private companies approved by Medicare); †Values < 5, or values that could be used to derive such values, have been suppressed to protect patient confidentiality
EGFR, epidermal growth factor receptor; NCCN, National Comprehensive Cancer Network; SD, standard deviation; VEGF, vascular endothelial growth factor